

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Klaus PREISSNER et al.)	Group Art Unit: Not yet assigned
)	
Application No.: Not yet assigned)	Examiner: Not yet assigned
)	
Filed: Herewith)	
)	
For: PHARMACEUTICAL PREPARATION)	
WITH RNA AS HEMOSTASIS)	
COFACTOR)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants brings to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed concurrently with the above-referenced application.

Copies of the listed documents, including any copending patent applications, are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

In lieu of a statement of relevance or translation of the non-English document DE 199 03 693 A1, its U.S. counterpart patent, U.S. Patent No. 6,528,299, is provided.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: July 30, 2003

By: Carol P. Einaudi
Carol P. Einaudi
Reg. No. 32,220

565662_1

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06478.1491	Appln. No.	Not yet assigned
Applicant	Klaus PREISSNER et al.		
Filing Date	Herewith	Group:	Not yet assigned

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	A	6,528,299 B1	03/04/03	Roemisch et al.	435	219	04/21/99

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	B	DE 199 03 693 A1	10/28/99	Germany			No; See Reference A

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Landré et al., Human Endothelial Cells Selectively Express Large Amounts of Pancreatic-Type Ribonuclease (RNase 1), <i>Journal of Cellular Biochemistry</i> , 86:540-552 (2002).

Examiner	Date Considered
----------	-----------------

*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
------------	--

Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce
---------------	---

565605_1